T1	intervention 0 10	Carvedilol
T2	condition 29 64	Chemotherapy-Related Cardiotoxicity
T3	No-of-participants 369 372	200
T4	eligibility 373 509	patients with HER2-negative breast cancer tumor status and normal left ventricular ejection fraction (LVEF) referred for ANT (240 mg/m2)
T5	control 535 542	placebo
T6	outcome-Measure 599 649	prevention of a ≥10% reduction in LVEF at 6 months
T7	outcome-Measure 675 765	effects of carvedilol on troponin I, B-type natriuretic peptide, and diastolic dysfunction
T8	outcome 767 783	Primary endpoint
T9	intervention-value 796 798	14
T10	intervention-value 809 814	14.5%
T11	control-value 844 846	13
T12	control-value 857 862	13.5%
T13	outcome 914 959	changes of LVEF or B-type natriuretic peptide
T14	outcome 1001 1055	difference existed between groups in troponin I levels
T15	outcome 1144 1178	incidence of diastolic dysfunction
T16	outcome 1274 1311	increase in LV end-diastolic diameter
